Zimmer Biomet (NYSE: ZBH) today announced it completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company developing semi- and fully autonomous surgical systems.
The deal adds new robotic capabilities to Zimmer Biomet’s growing surgical robotics portfolio. The company said Monogram’s surgeon-guided, CT-based systems will complement its existing Rosa Robotics platform and other navigation and mixed-reality tools used in joint replacement and other orthopedic procedures. The deal was previously announced in July.
“By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings,” CEO Ivan Tornos said. “We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy.”
Related: The top surgical robotics stories of 2025 so far
Monogram’s semi-autonomous total knee arthroplasty system received FDA 510(k) clearance in March 2025, with commercialization planned alongside Zimmer Biomet implants by early 2027. The company began a clinical study in July 2025 for its fully autonomous version.
The acquisition also allows Zimmer Biomet to offer CT-based and imageless robotic options while developing one of the first fully autonomous surgical robotic systems. It further strengthens its competitive position against other orthopedic surgical robot developers like Stryker, Smith+Nephew and Johnson & Johnson.
Under the merger agreement, each outstanding share of Monogram common stock converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory and revenue milestones are met by 2030.
Monogram shares stopped trading on Nasdaq before the market opened Oct. 7 and will be delisted.
Take a deeper dive into the surgical robotics market in MassDevice’s Surgical Robotics Special Report here.
